natgillin/translations-raw huggingface dataset:
These are produced by a method known as ‘recombinant DNA technology': they are made by a yeast that has received a gene (DNA), which makes it able to produce the proteins. 
• površinski antigen (beljakovine s površine) virusa hepatitisa B. Te beljakovine so pridobljene z metodo, imenovano „tehnologija rekombinantne DNA“, pri kateri kvasovka prejeme gen (DNA), s
The marketing authorisation was renewed on 7 May 2004. 
Dovoljenje za promet je bilo
PROCOMVAX is not recommended for infants younger than six weeks of age, because of a risk of a reduced protective response to Hib. 
Zaradi tveganja za zmanjšanje imunskega odziva na Hib uporaba zdravila PROCOMVAX pri dojenčkih, mlajših od šest tednov, ni priporočljiva.
The tmax was delayed by two hours. 
Tmax je bil zakasnjen za dve uri.
Frequencies are defined as very common (≥ 1/10), 
Pogostnost je definirana kot zelo pogosti (≥ 1/10),
Date of first authorisation: 06 March 2003 Date of latest renewal: 06 March 2008 
Datum prve odobritve: 6. marec 2003 Datum zadnjega podaljšanja: 6. marec 2008
4.8 Undesirable effects a. Summary of the safety profile 
4.8 Neželeni učinki a. Povzetek varnostnega profila
Clinical efficacy and safety: 
Klinična učinkovitost in varnost:
• Take care not to infect other people. 
• Pazite, da ne okužite drugih.
If you do get any of them, it is unlikely to be serious, but you need to check. 
Če jih imate, ni verjetno, da so resni, vendar je treba preveriti.
Wait and take the next dose at the regular time. 
Počakajte in vzemite naslednji odmerek ob običajnem času.
• If you are over 65 years of age your doctor may monitor your health more closely. 
• Če ste starejši od 65 let, bo morda zdravnik bolj pozorno nadzoroval vaše zdravje.
A risk to the newborns/infants cannot be excluded. 
Tveganja za dojene novorojence/otroke ne moremo izključiti.
The optimum duration of treatment is unknown. 
Optimalna dolžina zdravljenja ni znana.
As data becomes available 
Ko bodo podatki na voljo
Do not take a double dose (two doses close together). 
Ne vzemite dvojnega odmerka (dveh odmerkov enega za drugim).
• Tell your doctor immediately if you are pregnant or planning to become pregnant. 
• Nemudoma povejte zdravniku, če ste noseči ali če načrtujete nosečnost.
• If you are HIV positive this medicine will not control your HIV infection. 
• Če ste HIV pozitivni, to zdravilo ne bo nadzorovalo vaše okužbe s HIV.
What it is used for 
Za kaj ga uporabljamo
The frequency of the following side effects is not known (frequency cannot be estimated from the available data): 
Pogostnost naslednjih neželenih učinkov ni znana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov):
• Do not use Hepsera in children or adolescents under 18 years of age. 
• Zdravila Hepsera ne uporabljajte pri otrocih ali mladostnikih, mlajših od 18 let.
Exacerbation of hepatitis: 
Poslabšanje hepatitisa:
30 tablets. 
30 tablet.
People with liver disease may also be at risk. 
Tudi osebe z boleznijo jeter so izpostavljene tveganju.
You may need blood tests for several months after treatment. 
Krvne preiskave bodo morda potrebne tudi nekaj mesecev po prenehanju zdravljenja.
Elderly: The clinical experience in patients > 65 years of age is very limited. 
Starejši: Klinične izkušnje zdravljenja bolnikov starejših od 65 let so zelo omejene.
This is to make sure that your medicine is fully effective and to reduce the development of resistance to the treatment. 
S tem zagotovite popolno učinkovitost zdravila in zmanjšate možnost razvoja odpornosti na zdravljenje.
The risk of this occurring is increased with long-term use of Hepsera. 
Tveganje, da do tega pride, se z dolgotrajno uporabo zdravila Hepsera poveča.
The safety data derived from 5 pivotal randomized controlled studies, including a total of 1,174 patients, were reviewed. 
Pregledani so bili podatki o varnosti, ki izhajajo iz 5 ključnih randomiziranih, nadzorovanih študij, v katere je bilo skupno vključenih 1.174 bolnikov.
This leaflet was last revised in {MM/YYYY}. 
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}
You must continue to take precautions to avoid this. 
Zato morate nadaljevati zaščitne ukrepe, ki to preprečujejo.
common (≥ 1/100, < 1/10), uncommon (≥ 1/1000, < 1/100) or not known (identified through postmarketing safety surveillance and the frequency cannot be estimated from the available data). 
pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1000, < 1/100) ali pogostnost neznana (neželeni učinki opaženi pri spremljanju varnosti po pridobitvi dovoljenja za promet in trženju zdravila in njihove pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
Lactic acidosis occurs more often in women, particularly if they are very overweight. 
Laktacidoza se pogosteje pojavlja pri ženskah, zlasti če imajo zelo povečano telesno maso.
• Do not take Hepsera if you are taking any medicines containing tenofovir. 
• Ne jemljite zdravila Hepsera, če jemljete katero koli zdravilo, ki vsebuje tenofovir.
As adefovir is structurally related to nucleoside analogues, this risk cannot be excluded. 
Ker je adefovir strukturno soroden analogom nukleozidov, tega tveganja ne moremo izključiti.
Increases in creatinine 
povišanje kreatinina
It can cause too much lactic acid in the blood and enlargement of the liver. 
Lahko povzroči preveliko količino mlečne kisline v krvi in povečanje jeter.
Pharmacokinetic studies have not been conducted in the elderly. 
Farmakokinetične raziskave niso bile izvedene pri starejših.
• Kidney problems, as shown by blood tests 
• težave z ledvicami, ki se pokažejo pri krvnih preiskavah
Some of the signs of lactic acidosis are: 
Nekateri znaki laktacidoze so:
Five patients achieved and maintained HBsAg seroconversion (HBsAg negative/HBsAb positive). 
Pet bolnikov je doseglo in ohranilo HBsAg serokonverzijo (HBsAg negativni/anti-HBs pozitivni).
• pentamidine, for other types of infection. 
• pentamidin proti drugim vrstam okužb.
Hepsera with food and drink 
Zdravilo Hepsera skupaj s hrano in pijačo
• Tell your doctor if you have had kidney disease, or if tests have shown problems with your kidneys. 
• Povejte zdravniku, če imate bolezen ledvic ali če so preiskave pokazale, da imate težave z ledvicami.
Gender, age and ethnicity: The pharmacokinetics of adefovir were similar in male and female patients. 
Spol, starost in pripadnost etnični skupini: Farmakokinetične lastnosti adefovirja so bile podobne pri moških in ženskih bolnikih.
Improvement in liver function was also seen after one year of therapy. 
Prav tako so po enem letu zdravljenja opazili izboljšanje jetrne funkcije.
• If it is nearly time for your next dose, skip the missed dose. 
• Če je že skoraj čas za naslednji odmerek, pozabljenega odmerka ne vzemite.
With prolonged treatment for more than 2 years, regular reassessment is recommended to confirm that continuing the selected therapy remains appropriate for the patient. 
Če je zdravljenje podaljšano na več kakor 2 leti, je priporočljivo redno ponovno ocenjevanje zdravljenja za potrditev, da nadaljevanje z izbranim načinom zdravljenja za bolnika ostaja primerno.
The use of adefovir dipivoxil must be accompanied by the use of effective contraception. 
Uporabo dipivoksiladefovirata mora spremljati uporaba učinkovite kontracepcije.
Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in škatli poleg oznake {EXP}.
It's best for your doctor to monitor your health after stopping treatment with Hepsera. 
Zato je najbolje, da zdravnik nadzoruje vaše zdravje po prekinitvi zdravljenja z zdravilom Hepsera.
In case of emergence of resistance, treatment should be modified. 
Če se pojavi odpornost, je treba zdravljenje prilagoditi.
It is not known whether the active substance in this medicine passes into breast milk. 
Ni znano, ali učinkovina v tem zdravilu prehaja v materino mleko.
• Digestive problems including wind or discomfort after eating meals 
• prebavne težave, vključno z vetrovi ali neprijetnim občutkom po obroku
• look out for possible signs of lactic acidosis - see section 4, Possible side effects. 
• bodite pozorni na morebitne znake laktacidoze - glejte poglavje 4 Možni neželeni učinki;
On the basis of these data, the frequency of these adverse drug reactions is calculated to be 0.4% corresponding to the frequency category uncommon. 
Na osnovi teh podatkov je bila preračunana pogostnost teh neželenih učinkov zdravila 0,4 %, kar ustreza kategoriji pogostnosti “občasni”.
Patients should be monitored every six months for hepatitis B biochemical, virological and serological markers. 
Vsakih šest mesecev je potrebno pri bolnikih nadzorovati biokemične, virološke in serološke označevalce hepatitisa B.
It is not known whether Hepsera is safe to use during human pregnancy. 
Ni znano, ali je pri človeku uporaba zdravila Hepsera med nosečnostjo varna.
Treatment with 10 mg adefovir dipivoxil has not been shown to be effective against HIV replication and therefore should not be used to control HIV infection. 
Zdravljenje s 10 mg dipivoksiladefovirata se ni pokazalo kot učinkovito proti replikaciji HIV in se zato naj ne bi uporabljalo za nadzorovanje okužbe s HIV.
A vaccine is available to protect those at risk from becoming infected with HBV. 
Za zaščito oseb s tveganjem za okužbo s HBV je na voljo cepivo.
• Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines and herbal products obtained without a prescription. 
• Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, vključno z zdravili in izdelki rastlinskega izvora, ki ste jih dobili brez recepta.
Return any left over tablets to your pharmacist. 
Preostale tablete vrnite farmacevtu.
The adverse reactions considered at least possibly related to treatment are listed below, by body system organ class, and frequency (see Table 1). 
Neželeni učinki za katere se smatra, da so bili vsaj možno povezani z zdravljenjem, so navedeni spodaj po organskih sistemih in pogostnosti (glejte preglednico 1).
The relationship between treatment response and long-term outcomes such as hepatocellular carcinoma or decompensated cirrhosis is not known. 
Povezava odgovora na zdravljenje z dolgoročnimi posledicami kot so hepatocelularni karcinom ali dekompenzirana ciroza ni poznana.
At concentrations substantially higher (> 4,000-fold) than those observed in vivo, adefovir did not inhibit any of the following human CYP450 isoforms, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4. 
Pri koncentracijah občutno višjih (> 4.000 krat) kot tistih opaženih in vivo ni adefovir zaviral nobenega od naslednjih humanih CYP450 izoformov: CYP1A2, CYP2D6, CYP2C9, CYP2C19 in CYP3A4.
No clinically significant changes in renal function were observed. 
Klinično pomembne spremembe ledvične funkcije niso bile opažene.
Paediatric population: 
Pediatrični populacija:
Pharmacotherapeutic group: Nucleoside and nucleotide reverse transcriptase inhibitors, ATC code: J05AF08. 
Farmakoterapevtska skupina: zaviralci nukleozidne in nukleotidne reverzne transkriptaze, oznaka ATC: J05AF08.
See section 2 for more details. 
Podrobnosti so v poglavju 2.
The available data do not appear to indicate any difference in pharmacokinetics with regard to race. 
Podatki, ki so na voljo, ne kažejo nobenih razlik farmakokinetičnih lastnosti glede na raso.
• HBeAg positive and HBeAg negative chronic hepatitis B with compensated liver disease. 
• HBeAg pozitivnim in HBeAg negativnim kroničnim hepatitisom B s kompenzirano boleznijo jeter.
In a long-term safety study of 125 HBeAg negative patients with compensated liver disease, the adverse event profile was overall unchanged after a median exposure of 226 weeks. 
V dolgoročni študiji varnosti s 125 HBeAg negativnimi bolniki s kompenzirano boleznijo jeter je bil profil neželenih učinkov na splošno nespremenjen po mediani izpostavljenosti 226 tednov.
The recommended dosing frequency according to renal function must not be exceeded (see sections 4.4 and 5.2). 
Priporočena pogostnost odmerjanja glede na ledvično funkcijo se ne sme prekoračiti (glejte poglavji 4.4 in 5.2).
• Kidney problems may lead to softening of the bones (which causes bone pain and sometimes leads to fractures) and muscle pain or weakness. 
• težave z ledvicami lahko povzročijo mehčanje kosti (kar povzroči bolečine v kosteh in včasih zlom), bolečine v mišicah ali mišično oslabelost;
d. Paediatric population 
d. Pediatrična populacija
Hepsera reduces the amount of the virus in your body, and has been shown to reduce liver damage. 
Zdravilo Hepsera zmanjša količino virusa v vašem telesu in s tem zmanjša poškodbo jeter.
Asthenia c. Description of selected adverse reactions 
astenija c. Opis izbranih neželenih učinkov
Nonetheless, there is a potential risk of selection of HIV strains resistant to adefovir with possible cross-resistance to other antiviral medicinal products. 
Kljub temu pa obstaja potencialno tveganje, da se izbere HIV seve, ki so odporni proti adefovirju z možno navzkrižno odpornostjo na druga protivirusna zdravila.
• Also tests may show decreases in phosphate (common) or increases in creatinine (very common) in the blood. 
• Preiskave lahko pokažejo tudi znižanje fosfatov (pogosto) ali zvišanje kreatinina (zelo pogosto)
Patients were all HBeAg positive and had median CD4 cell count of 441 cells/mm3 (no patient had CD4 count < 200 cells/mm3). 
Vsi bolniki so bili pozitivni za HBeAg in so imeli srednje število celic CD4 441 celic/mm3 (pri nobenem bolniku število celic CD4 ni bilo < 200 celic/mm3).
These patients should be closely monitored for possible adverse reactions and to ensure efficacy is maintained. 
Te bolnike je potrebno skrbno nadzorovati zaradi možnega pojava neželenih učinkov in da se zagotovi ohranitev učinkovitosti.
The proposed dose interval modification is based on extrapolation of limited data in patients with end stage renal disease (ESRD) and may not be optimal. 
Predlagane spremembe intervalov med odmerki temeljijo na ekstrapolaciji manjšega števila podatkov pri bolnikih z ledvičnim obolenjem v končni fazi (ESRD, end stage renal disease) in morda niso optimalne.
The clinical significance of these findings as they relate to histological improvement is not known. 
Klinična pomembnost teh odkritij, glede na histološko izboljšanje, ni poznana.
Improvements or stabilisation were seen in Child-Pugh-Turcotte score. 
Izboljšanje ali stabilizacijo je prikazala lestvica po Child-Pugh-Turcotte.
These patients should be closely monitored for possible adverse reactions and to ensure efficacy is maintained (see sections 4.4 and 4.8). 
Te bolnike je treba skrbno nadzorovati zaradi možnega pojava neželenih učinkov in zato da se zagotovi ohranitev učinkovitosti (glejte poglavji 4.4 in 4.8).
Overall, the safety profile of adefovir dipivoxil in children was consistent with the known safety profile in adult patients. 
Varnostni profil dipivoksiladefovirata pri otrocih je bil na splošno podoben znanemu varnostnemu profilu pri odraslih bolnikih.
• your doctor should order blood tests every three months to check your medicine is keeping your chronic hepatitis B infection under control. 
• mora zdravnik vsake tri mesece naročiti analizo krvi, da preveri, ali je z zdravilom nadzorovana kronična okužba z virusom hepatitisa B.
These patients should be followed closely. 
Te bolnike je potrebno skrbno nadzorovati.
Treatment discontinuation may be considered as follows: 
Prekinitev zdravljenja je potrebno presoditi v naslednjih primerih:
If viral rebound occurs, resistance testing should be performed. 
Če se pojavi virusni povratni odziv, je treba opraviti testiranje za odpornost.
Do not store above 30ºC. 
Shranjujte pri temperaturi do 30 °C.
The tablets are marked with “GILEAD” and “10” on one side and a stylised shape of a liver on the other side. 
Na tabletah sta napisa “GILEAD” in “10” na eni strani ter stiliziran obris jeter na drugi.
No adverse effects on development were seen at systemic exposures approximately 12 times that achieved in humans at the therapeutic dose. 
Nobenih neželenih učinkov za razvoj pa ni bilo opaženih pri približno 12 krat večji sistemski izpostavljenosti, kot je dosežena pri človeku s terapevtskimi odmerki.
Therefore, the standard recommended procedures for immunisation of infants should be followed to prevent neonatal acquisition of HBV. 
Zato se morajo upoštevati običajna priporočila za imunizacijo dojenčka, da se s tem prepreči okužba novorojenčka s HBV.
Diarrhoea, vomiting, abdominal pain, dyspepsia, nausea, flatulence 
diareja, bruhanje, abdominalna bolečina, dispepsija, navzea, flatulenca
Other medicines and Hepsera 
Druga zdravila in zdravilo Hepsera
Even though a pharmacokinetic interaction is unlikely given the two products are eliminated via different pathways, caution is recommended if both products are co-administered. 
Čeprav je farmakokinetično medsebojno delovanje manj verjetno, ob upoštevanju tega, da se zdravili izločata prek različnih poti, se pri sočasnem jemanju priporoča previdnost.
Some patients have had symptoms or blood tests indicating that their hepatitis has worsened after stopping treatment with Hepsera. 
Nekateri bolniki so imeli simptome oziroma rezultate analize krvi, ki so pokazali, da se je po prenehanju zdravljenja z zdravilom Hepsera hepatitis še poslabšal.
Improvement was defined as a reduction from baseline of two points or more in the Knodell necro-inflammatory score with no concurrent worsening in the Knodell fibrosis score. 
Izboljšanje je bilo definirano kot zmanjšanje za dve ali več točk od začetne vrednosti po Knodellovi nekroinflamatorni lestvici brez sočasnega poslabšanja po Knodellovi fibrozni lestvici.
90 (3 bottles of 30) tablets. 
90 (3 plastenke po 30) tabletami.
Hepsera does not reduce the risk of passing on HBV to others through sexual contact or blood contamination. 
Zdravilo Hepsera ne zmanjšuje tveganja za prenos okužbe z virusom HBV s spolnimi odnosi ali kontaminacijo krvi.
There are only limited data on the safety and efficacy of this dosing interval adjustment guideline. 
Podatki o varnosti in učinkovitosti teh smernic za prilagajanje intervalov med odmerki so omejeni.
In over two thirds of patients suppression of serum HBV DNA was associated with normalisation of ALT levels. 
Pri več kot dveh tretjinah bolnikov je bila supresija serumske HBV DNA povezana z normalizacijo vrednosti ALT.
• foscarnet, cidofovir or tenofovir disoproxil fumarate, for viral infections 
• foskarnet, cidofovir ali dizoproksiltenofovirat fumarat proti virusnim okužbam;
Do not store above 30ºC (86ºF). 
Shranjujte pri temperaturi do 30 °C (86 °F).
In the event of these patients developing renal insufficiency, see above Renal function. 
V primeru, da ti bolniki razvijejo ledvično insuficienco, glejte zgoraj pod Ledvična funkcija.
A four-hour period of haemodialysis removed approximately 35 % of the adefovir dose. 
S štiri ure trajajočo hemodializo se je izločilo približno 35% odmerka adefovirja.
Absorption: The oral bioavailability of adefovir from 10 mg adefovir dipivoxil is 59 %. 
Absorbcija: Oralna biološka razpoložljivost adefovirja iz 10 mg dipivoksiladefovirata je 59%.
Hepsera can be taken with or without food. 
Zdravilo Hepsera se lahko jemlje s hrano ali brez nje.
Patients with creatinine clearance between 30 and 49 ml/min: 
Bolniki z očistkom kreatinina od 30 do 49 ml/min:
Treatment with nucleoside analogues should be discontinued when rapidly elevating aminotransferase levels, progressive hepatomegaly or metabolic/lactic acidosis of unknown aetiology occur. 
Zdravljenje z analogi nukleozidov se mora prekiniti, če se pojavi hitro naraščujoč nivo vrednosti aminotransferaze, napredujoča hepatomegalija ali metabolična acidoza/laktacidoza neznane etiologije.
The clinical significance of these observed changes in HBV DNA has not been established. 
Klinična pomembnost teh sprememb opaženih za HBV DNA ni ugotovljena.
Because of insufficient data on safety and efficacy, Hepsera should not be used in children under the age of 18 years (see Sections 4.2 and 5.1). 
Ker so podatki o varnosti in učinkovitosti nezadostni, se zdravilo Hepsera se ne sme uporabljati pri otrocih, starih do 18 let (glejte poglavji 4.2 in 5.1).
If you stop taking Hepsera 
Če ste prenehali jemati zdravilo Hepsera
Due to their limitations, the clinical data available do not allow to draw definitive conclusions on the benefit/risk ratio of the adefovir treatment in children with chronic hepatitis B (see section 4.2). 
Zaradi omejenosti razpoložljivih kliničnih podatkov ni mogoče dokončno sklepati o razmerju koristi in tveganja zdravljenja z adefovirjem pri otrocih s kroničnim hepatitisom B (glejte poglavje 4.2).
• Lactic acidosis is a serious but very rare side effect of taking Hepsera. 
• Laktacidoza je resen, vendar zelo redek neželeni učinek pri jemanju zdravila Hepsera.
The median (min-max) renal clearance of adefovir in subjects with normal renal function (Clcr > 80 ml/min) is 211 ml/min (172-316 ml/min), approximately twice calculated creatinine clearance (Cockroft-Gault method). 
Mediani (min-max) ledvični očistek adefovirja pri osebah z normalno ledvično funkcijo (CLCR > 80 ml/min) je 211 ml/min (172-316 ml/min), kar je približno dvakratna vrednost očistka kreatinina (Cockroft-Gault metoda).
• compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis. 
• kompenzirano boleznijo jeter z dokazom aktivne virusne replikacije, z vztrajno povišano vrednostjo serumske alanin-aminotransferaze (ALT) in histološkim dokazom aktivnega vnetja jeter in fibroze.
• Once you start taking Hepsera: 
• Po začetku jemanja zdravila Hepsera:
In patients with decompensated liver disease, adefovir should always be used in combination with a second agent, without cross-resistance to adefovir, to reduce the risk of resistance and to achieve rapid viral suppression. 
Pri bolnikih z dekompenzirano boleznijo jeter je treba adefovir vedno uporabiti v kombinaciji z drugo učinkovino, ki ni navzkrižno rezistentna za adefovir, za zmanjšanje tveganja rezistence in doseganje hitrega zavrtja virusa.
Initiation of Hepsera treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate (see section 5.1). 
O zdravljenju z zdravilom Hepsera razmislite šele, ko uporaba alternativnih protivirusnih učinkovin z višjo gensko pregrado za rezistenco ni na voljo ali ni ustrezna (glejte poglavje 5.1).
Elderly: No data are available to support a dose recommendation for patients over the age of 65 years (see section 4.4). 
Starejši: Podatkov, na osnovi katerih bi lahko priporočili odmerke za bolnike starejše od 65 let, ni na voljo (glejte poglavje 4.4).
• Tell your doctor immediately about any new, unusual or worsening symptoms that you notice after stopping treatment. 
• Takoj povejte zdravniku, če opazite nove ali nenavadne simptome ali poslabšanje simptomov, ki jih opazite po prenehanju zdravljenja.
Benign digestive symptoms, such as nausea, vomiting and abdominal pain, might be indicative of lactic acidosis development. 
Benigni prebavni simptomi kot so navzea, bruhanje in abdominalna bolečina lahko nakazujejo razvoj laktacidoze.
• Tell your doctor at once if you could be allergic to adefovir, adefovir dipivoxil or any of the other ingredients of Hepsera. 
• Takoj obvestite svojega zdravnika, če obstaja možnost, da ste alergični na adefovir, dipivoksiladefovirat ali katero koli sestavino zdravila Hepsera.
Each bottle contains 30 tablets, silica gel desiccant and fibre packing material. 
Vsaka plastenka vsebuje 30 tablet, silikagelsko sušilo in vlaknast ovojni material.
However, based on the safety profile and mechanism of action, adefovir dipivoxil is expected to have no or negligible influence on these abilities. 
Vendar se na podlagi varnostnega profila in mehanizmov delovanja pričakuje, da dipivoksiladefovirat nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
• Don't stop taking Hepsera without your doctor's advice. 
• Zdravila Hepsera ne prenehajte jemati brez posveta z zdravnikom.